As of June 6, 2025, Pfizer Inc., with its stock symbol PFE, is trading at $23.39 per share. This price represents a slight increase of 0.17 percent from the previous day. The trading volume for Pfizer stock on June 4, 2025, was 24,500,119 shares, which is significantly higher than the average trading volume.

Pfizer has been in the news recently for its ongoing efforts to combat COVID-19. The company has been developing a vaccine to help prevent COVID-19, which has been a major focus for the pharmaceutical industry. Additionally, Pfizer is working on an investigational protease inhibitor, further expanding its portfolio of COVID-19 treatments.

In terms of analyst updates, recent reports suggest that Pfizer's stock has been underperforming compared to its peers. The stock price has fallen by 3.35 percent over the past month and by 21.79 percent over the past year. However, some analysts still see potential for growth, with price estimates ranging from $23.00 to $35.00 per share.

The company's financial performance and product pipeline have been key areas of focus for investors. Pfizer's product pipeline includes several promising candidates, and the company has been making significant strides in regulatory submissions and clinical trial results. Despite these positive developments, the stock's performance has been impacted by broader market conditions and the ongoing challenges in the pharmaceutical industry.

Overall, while Pfizer's stock price has experienced some volatility, the company's commitment to innovation and its robust product pipeline suggest that it remains a significant player in the pharmaceutical sector. Investors should continue to monitor the company's financials, product developments, and market trends to make informed decisions about their investments in Pfizer stock.

For more http://www.quietplease.ai

Stock up on these deals
https://amzn.to/3QFpYIX

As of today, June 4, 2025, Pfizer's stock price is $23.49 per share, with a trading volume of 56,618,550 shares. This volume is significantly higher than the average trading volume, indicating a high level of investor interest in the company. The day's high was $23.62, and the day's low was $23.16, reflecting a relatively stable trading session.

Pfizer has been in the news recently due to its pipeline of drugs, which analysts believe will significantly impact the company's future performance. According to recent analyst updates, Pfizer's share price is expected to range between $24 and $75 in 2025, driven by the potential of its pipeline drugs[2]. This wide range indicates a mix of optimism and caution among analysts regarding the company's future prospects.

In terms of recent news, Pfizer has been actively involved in various clinical trials and regulatory submissions for new treatments. The company's commitment to innovation and its robust pipeline of drugs has been a major driver of investor confidence. Additionally, Pfizer has been making strategic investments in biotechnology and pharmaceutical research, further enhancing its position in the industry.

The historical stock chart shows that Pfizer's stock has been relatively stable over the past few months, with a 52-week high of $31.54 and a 52-week low of $20.92[4]. This stability is a testament to the company's strong fundamentals and its ability to navigate the ever-changing landscape of the pharmaceutical industry.

Overall, Pfizer's stock appears to be well-positioned for future growth, driven by its promising pipeline of drugs and strategic investments in research and development. While there is a wide range of expected prices from analysts, the current trading volume and recent news suggest that investors are optimistic about the company's prospects. As we move forward into the rest of 2025, it will be interesting to see how these factors continue to influence Pfizer's stock performance.

For more http://www.quietplease.ai

Stock up on these deals
https://amzn.to/3QFpYIX

As of June 3, 2025, Pfizer's stock price is $23.46 USD, which represents a slight decrease of 0.68 percent in the past 24 hours. The trading volume for the day stands at 30,089,446 shares, which is significantly higher than the average volume of 54 million shares. This increased trading activity could be a result of investors' interest in the company's recent developments and future prospects.

Pfizer is one of the world's largest pharmaceutical firms, with annual sales nearing $50 billion, excluding COVID-19-related product sales. The company's product portfolio includes a range of prescription drugs and vaccines, with top sellers such as the pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. International sales account for nearly 50 percent of total sales, with emerging markets being a significant contributor.

Recently, Pfizer has been in the spotlight for its pipeline productivity, particularly with the successful launch of cardiovascular drug Vyndaqel. This drug is seen as a potential game-changer in the rare-disease arena, which could significantly boost Pfizer's revenue in the coming years. However, there are also concerns about aggressive cost-cutting in research and development, which could impact the company's long-term prospects if not managed properly.

Major analysts have provided mixed forecasts for Pfizer's future performance. According to some analysts, the stock price could reach as high as $35.00 USD, while others predict a minimum of $23.00 USD. The current fair value estimate by Morningstar is $91.00 USD, indicating a significant discount in the current market price.

Overall, Pfizer's stock performance is influenced by a combination of its robust product pipeline, international sales, and ongoing research efforts. While there are concerns about cost-cutting measures, the company's recent successes and future potential make it an attractive investment opportunity for many investors. As always, it is crucial to conduct thorough research and consider multiple factors before making any investment decisions.

For more http://www.quietplease.ai

Stock up on these deals
https://amzn.to/3QFpYIX

As of June 2, 2025, Pfizer's stock price stands at $23.49, with a trading volume of 56,618,550 shares. This volume is significantly higher than the average, indicating a high level of investor interest in the company. The stock has seen a slight increase of 0.04 dollars from the previous day, representing a 0.17 percent rise.

Pfizer has been in the news recently due to its ongoing efforts in the pharmaceutical industry. The company has been at the forefront of vaccine development, particularly with its COVID-19 vaccine, which has been a major contributor to its financial success. Additionally, Pfizer has been making significant strides in cancer treatment and other therapeutic areas, which has garnered attention from both investors and analysts.

Major analysts have been updating their price targets for Pfizer stock. WalletInvestor projects a mixed trajectory for Pfizer shares in 2025, with slight rises and falls, and a price range of $23.83 to $28.10 by the end of the year. On the other hand, PandaForecast anticipates sustained growth, with the stock price stabilizing in January and reaching highs of around $40.15 by December 2025.

In terms of recent news, Pfizer has been making headlines with its ongoing research and development in various therapeutic areas. The company has also been involved in several strategic partnerships and acquisitions, which are expected to further enhance its market position. These developments have contributed to the optimism among investors and analysts regarding Pfizer's future prospects.

Overall, while there are varying forecasts for Pfizer's stock performance in 2025, the current price and trading volume suggest a strong interest in the company. The ongoing research and development, coupled with strategic partnerships, position Pfizer well for continued growth and stability in the pharmaceutical industry.

For more http://www.quietplease.ai

Stock up on these deals
https://amzn.to/3QFpYIX

As of today, May 30, 2025, Pfizer's stock price is $23.18 per share. This is slightly lower than the previous closing price of $23.45 on May 29, 2025. The stock has been trading within a relatively narrow range over the past few days, with an intraday high of $23.45 and a low of $22.88 on May 23, 2025[3].

In terms of trading volume, Pfizer's stock has seen significant activity. On May 23, 2025, the stock traded 35,405,386 shares, which is a substantial volume compared to its average trading volume[3]. This high trading activity could be indicative of investor interest and potential market sentiment.

There have been no major recent news announcements that could significantly impact Pfizer's stock price. However, it is worth noting that the company has been under scrutiny for its performance and market valuation. Morningstar, for instance, has indicated that Pfizer is trading at a 45% discount to its fair value, which is $42.00 per share as of May 28, 2025[4].

Major analysts have also provided updates on Pfizer's stock. StockInvest.us, for example, has predicted a fair opening price of $23.35 for May 30, 2025, and suggests that the stock may move between $22.88 and $24.02 during the day, indicating a possible trading interval of plus or minus $0.573 (or 2.44 percent) from the last closing price[5]. However, their analysis also indicates that the stock is closer to resistance from accumulated volume at $23.79 than support at $22.97, making the trading risk/reward intra-day unattractive.

Overall, while there are no immediate catalysts for a significant price movement, the stock's performance will likely be influenced by broader market trends and investor sentiment. Given the current market conditions and analyst predictions, it seems that Pfizer's stock is poised for a relatively stable day with potential for minor fluctuations within a narrow trading range.

For more http://www.quietplease.ai

Stock up on these deals
https://amzn.to/3QFpYIX

As of May 29, 2025, Pfizer's stock price stands at $23.32, which is a significant drop from its all-time high of $51.62 on December 16, 2021. The current price is also below the 52-week high of $31.54 and above the 52-week low of $20.92. The average stock price for the last 52 weeks is $26.84, indicating a relatively stable trend despite the fluctuations.

The trading volume for Pfizer stock has been substantial, with 35,405,386 shares traded on May 23, 2025, according to historical data. This volume is indicative of investor interest and activity in the stock.

Recently, there have been no major announcements from Pfizer that could significantly impact the stock price. However, the company continues to be a leader in the pharmaceutical industry, with a diverse portfolio of drugs and vaccines. The ongoing development of new treatments and the company's commitment to healthcare innovation are likely to maintain investor confidence.

Major analysts have not made any significant updates or changes to their price targets for Pfizer stock recently. However, forecasts suggest that the stock could see some growth in the coming months. For example, one forecast indicates that the stock could start at $35.40 in May 2025, with a maximum of $39.00 and a minimum of $33.22, averaging at $35.93 by the end of the month[5].

In summary, while Pfizer's stock price has experienced some volatility, the company's strong position in the pharmaceutical industry and ongoing innovation efforts are likely to support its value. Investors should continue to monitor the stock for any significant updates or announcements that could impact its performance.

For more http://www.quietplease.ai

Stock up on these deals
https://amzn.to/3QFpYIX

As of today, May 28, 2025, Pfizer's stock price is $23.32, which is slightly higher than the closing price of $23.32 on May 23, 2025[2]. The trading volume on May 23, 2025, was 35,405,386 shares, which is significantly higher than the average trading volume, indicating a high level of market activity[2].

Pfizer has been in the news recently due to its ongoing efforts in vaccine development and its role in addressing global health challenges. The company has been a leader in the COVID-19 vaccine market and continues to innovate in the field of biotechnology. This has contributed to its stable stock performance despite fluctuations in the broader market.

Major analysts have been monitoring Pfizer closely, particularly given its significant market presence and influence in the pharmaceutical industry. While there have been no major price target changes recently, analysts continue to evaluate the company's long-term prospects based on its pipeline of new treatments and ongoing research initiatives.

In terms of recent news, Pfizer has made several announcements regarding its financial performance and strategic partnerships. The company has reported strong earnings in recent quarters, which has helped maintain investor confidence. Additionally, Pfizer has been involved in several high-profile collaborations aimed at advancing medical research and improving healthcare outcomes.

The 52-week high for Pfizer's stock price was $31.54, which is 33.6 percent above the current share price. This indicates that while the stock has experienced some volatility, it remains a strong performer in the market. The 52-week low was $20.92, which is 11.4 percent below the current price, showing that the stock has maintained a relatively stable value over the past year[3].

Overall, Pfizer's stock performance is influenced by a combination of its strong financials, innovative research, and its role in addressing global health challenges. As the company continues to innovate and expand its product pipeline, investors remain optimistic about its future prospects.

For more http://www.quietplease.ai

Stock up on these deals
https://amzn.to/3QFpYIX

As of May 27, 2025, Pfizer's stock price stands at $23.32, which is a slight decrease from its recent highs. The trading volume for Pfizer has been substantial, with 35,405,386 shares changing hands on May 23, 2025, according to historical data. This volume is significantly higher than the average trading volume, indicating a high level of investor interest.

Recently, there have been several news updates and announcements that could impact Pfizer's stock performance. One significant development is the company's ongoing efforts in the field of biotechnology, particularly in the development of new vaccines and treatments. Pfizer has been at the forefront of the COVID-19 vaccine market, and its continued investment in research and development is likely to drive future growth.

Major analysts have also been updating their price targets for Pfizer. According to recent forecasts, Pfizer's stock is expected to rise to $25 by the middle of 2026 and then to $30 by the end of that year. By 2027, the forecast predicts a price of $35, followed by $40 by the middle of 2028, and eventually reaching $45 by 2028, $50 by 2029, $55 by 2030, $60 by 2032, $65 by 2034, $70 by 2035, and $75 by 2036[5].

These long-term forecasts suggest a steady increase in Pfizer's stock value over the next decade, driven by the company's continued innovation and market leadership. Additionally, the recent decrease in stock price could present an attractive buying opportunity for investors looking to capitalize on Pfizer's strong fundamentals and future growth prospects.

In summary, while Pfizer's current stock price is slightly lower than recent highs, the company's strong position in the biotechnology sector, coupled with positive analyst forecasts and substantial trading volume, make it an attractive investment option for those looking to the future.

For more http://www.quietplease.ai

Stock up on these deals
https://amzn.to/3QFpYIX

As of today, May 26, 2025, the current stock price of Pfizer, denoted by the stock symbol PFE, stands at $23.32 USD. This price reflects a slight increase from the previous day's closing price of $23.32 USD, with the stock having risen by 1.22% in the past 24 hours, according to TradingView[5]. The trading volume for Pfizer on this day was 35,405,386 shares, which is a significant amount but not unusually high compared to its average trading volume.

Looking at the broader picture, Pfizer's stock has shown some volatility in recent months. The 52-week high for Pfizer stock is $31.54, which is 35.2% above the current share price, while the 52-week low is $20.92, which is 10.3% below the current price. This indicates that while the stock has experienced some fluctuations, it remains relatively stable[1].

There have been no major recent news announcements specifically about Pfizer's stock that could significantly impact its price. However, the company has been in the spotlight for its ongoing efforts in vaccine development and pharmaceutical research, which could potentially influence investor sentiment in the long term.

Major analyst updates have also been relatively stable. Analysts' price estimates for Pfizer range from a minimum of $23.00 USD to a maximum of $35.00 USD, indicating a moderate level of optimism about the company's future performance[5]. Despite this, the stock has shown a decrease of 18.65% over the past year, which may be a concern for some investors.

In summary, while Pfizer's stock price remains relatively stable, it is influenced by broader market trends and the company's ongoing research and development activities. Investors should keep an eye on any future announcements or updates from the company to gauge potential changes in its stock performance.

For more http://www.quietplease.ai

Stock up on these deals
https://amzn.to/3QFpYIX

As of May 23, 2025, Pfizer's stock price stands at $23.52, which is a slight increase from its recent trading activity. The company's stock has been relatively stable, with a closing price of $23.52 on May 20, 2025, and an open price of $23.17 on the same day, according to historical data[4]. The trading volume on May 20, 2025, was 57,047,501 shares, which is significantly higher than the average trading volume, indicating a high level of investor interest.

Pfizer has been in the news recently for its ongoing efforts to develop new treatments and vaccines. The company's COVID-19 vaccine, developed in collaboration with BioNTech, has been a major contributor to its financial performance. Additionally, Pfizer has been investing heavily in its product pipeline, with several regulatory submissions and clinical trial results expected in the coming months[1].

Major analysts have been optimistic about Pfizer's future prospects. According to recent forecasts, the company's stock price is expected to rise to $35 by the middle of 2025 and then to $40 by the middle of 2027. By 2028, the stock is forecasted to reach $45, and by 2036, it could potentially hit $75[5]. These predictions are based on the company's strong financial performance and its continued investment in research and development.

In terms of recent news, Pfizer has announced several strategic initiatives aimed at enhancing its manufacturing capabilities and product supply. The company has also been actively involved in strategic reviews and capital allocation objectives, including plans for share repurchases and dividends[1]. These moves are expected to further boost investor confidence and drive the stock price upwards.

Overall, Pfizer's stock appears to be on a positive trajectory, driven by its robust financial performance, ongoing research and development efforts, and strategic business initiatives. As investors continue to monitor the company's progress, the stock price is likely to remain a point of interest in the market.

For more http://www.quietplease.ai

Stock up on these deals
https://amzn.to/3QFpYIX